Combination Immunotherapy With Interferon-gamma and Nivolumab for Patients With Advanced Solid Tumors: A Phase 1 Study
Phase of Trial: Phase I
Latest Information Update: 09 Feb 2018
At a glance
- Drugs Interferon gamma (Primary) ; Nivolumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 06 Feb 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2021.
- 06 Feb 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2019.
- 27 Feb 2017 According to a Horizon Pharma media release, safety data from the first two cohorts of this trial is presented at the American Society for Clinical Oncology - Society for Immunotherapy of Cancer meeting.